In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model

Cancer Biotherapy and Radiopharmaceuticals

Volumn 24, Issue 1, 2009, Pages 15-23

  Liu, Zhaofei ^a   Yu, Zilin ^a   He, Weiwei ^a   Ma, Shujun ^b   Sun, Le ^b   Wang, Fan ^a  

^a PEKING UNIVERSITY   (China)

^b Welson Pharmaceuticals Inc   (United States)

Author keywords

Epidermal growth factor receptor (EGFR); Immunoscintigraphy; Internalization; Monoclonal antibody LA22; Tumor targeting

Indexed keywords

DRUG CARRIER; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IODINE 125; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY LA22; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; DRUG UPTAKE; HUMAN; HUMAN CELL; INTERNALIZATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOTHERAPY; IODINE RADIOISOTOPES; MICE; MICE, INBRED BALB C; RADIONUCLIDE IMAGING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TEMPERATURE;

EID: 60849131263     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2008.0537     Document Type: Article

References (32)

1. Singh AB, Harris RC. Autocrine, paracrine, and juxtacrine signaling by EGFR ligands. Cell Sign 2005;17:1183.
2. Mendelsohn J, Baselga J. The EGF-receptor family as targets for cancer therapy. Oncogene 2000;19:6550.
3. Emir H, Michael S, Stefan H, et al. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface experession, and increased shedding of the urokinase plasminogen activator receptor. Gynecol Oncol 2006;101:28.
4. Grandis JR, Sok JC. Signaling through the epidermal growth factor receptor during the development of malignancy. Pharmacol Ther 2004;102:37.
5. Mendelsohn J, Baselga J. Status of epedermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787.
6. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett 2005;227:9.
7. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol 2005;5:343.
8. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137.
9. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr Opin Pharmacol 2005;5:543.
10. Bross PF, Beitz J, Chen G, et al. Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7:1490.
11. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res 2005;65:11631.
12. Shao W, Zhao S, Liu Z, et al. Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with antitumor antibiotics mitomycin C. Biochem Biophys Res Commun 2006;349:816.
13. 64Cu-DOTA- cetuximab in 5 cervical cancer cell lines. J Nucl Med. 2008;49:1472.
14. Reist CJ, Archer GE, Kurpad SN, et al. Tumor-specific antiepidermal growth factor receptor variant III monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts. Cancer Res 1995;55:4375.
15. Nordberg E, Friedman M, Göstring L, et al. Cellular studies of binding, internalization, and retention of a radiolabeled EGFR-binding affibody molecule. Nucl Med Biol 2007;34:609.
16. Perera RM, Zoncu R, Johns TG, et al. Internalization, intracellular trafficking, and biodistribution of monoclonal antibody 806: A novel antiepidermal growth factor receptor antibody. Neoplasia 2007;9:1099.
17. Lindmo T, Boven E, Cuttitta F, et al. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Meth 1984;72:77.
18. 3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004;45:1390.
19. 99mTc(I)-labeled bombesin analogue for imaging of gastrin releasing peptide receptor-positive tumors. Nucl Med Biol 2002;29:553.
20. Rosenblum MG, Cheung LH, Liu Y, et al. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003;63:3995.
21. Kirpotin DB, Drummond DC, Shao Y, et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 2006;66:6732.
22. Altenschmidt U, Schmidt M, Groner B, et al. Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin. Int J Cancer 1997;73:117.
23. Poul MA, Becerril B, Nielsen UB, et al. Selection of tumor-specific internalizing human antibodies from phage libraries. J Mol Biol 2000;301:1149.
24. Heldin CH. Dimerization of cell-surface receptors in signal transduction. Cell 1995;80:213.
25. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7:2958.
26. Speake G, Holloway B, Costello G. Recent developments related to the EGFR as a target for cancer chemotherapy. Curr Opin Pharmacol 2005;5:343.
27. Wu D, Wang L, Sato GH, et al. Human epidermal growth factor (EGF) receptor sequence recognized by EGF competitive monoclonal antibodies: Evidence for the localization of the EGF-binding site. J Biol Chem 1998;264:17469.
28. Wu D, Wang L, Chi Y, et al. Human epidemal growth factor receptor residue covalently cross-linked to epidermal growth factor. Proc Natl Acad Sci USA 1990;87:3151.
29. Astsaturov I, Cohen RB, Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets 2006;6:691.
30. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006;6:714.
31. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol 2005;23:1147.
32. Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor: Various factors, mechanisms involved, and its implications. Int Immunopharmacol 2003;3:319.